New drug application – Biasly

New drug application Follow

HOPO Therapeutics, Inc.: HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

Lead poisoning

HOPO Therapeutics, Inc.: HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy...

FinanzNachrichten.de
Oct 28, 2024

Somewhat Liberal

default thumbnail

United States Department of Health and Human Services

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

Financial Post
Oct 28, 2024

Somewhat Liberal

Aurinia Pharmaceuticals Partner Files NDA in Japan for Voclosporin

Japan

Aurinia Pharmaceuticals Partner Files NDA in Japan for Voclosporin

MarketWatch
Nov 13, 2023

Somewhat Liberal